(Q38041848)

27 August 2017

title

Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience (English)

1 reference

27 August 2017

1 reference

1 reference

1 reference

1 reference

rubella virus

1 reference

11

Stanley A Plotkin

1 reference

27 August 2017

Fabio Lievano

1

1 reference

27 August 2017

Susan A Galea

2

1 reference

27 August 2017

Michele Thornton

3

1 reference

27 August 2017

Richard T Wiedmann

4

1 reference

27 August 2017

Susan B Manoff

5

1 reference

27 August 2017

Trung N Tran

6

1 reference

27 August 2017

Manisha A Amin

7

1 reference

27 August 2017

Margaret M Seminack

8

1 reference

27 August 2017

Kristen A Vagie

9

1 reference

27 August 2017

Adrian Dana

10

1 reference

27 August 2017

language of work or name

English

0 references

publication date

7 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

30

1 reference

27 August 2017

issue

48

1 reference

27 August 2017

page(s)

6918-6926

1 reference

Mumps resurgences in the United States: A historical perspective on unexpected elements

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Measles in the United States during the postelimination era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Development and Evaluation of the Moraten Measles Virus Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Mumps outbreaks across England and Wales in 2004: observational study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Global use of rubella vaccines, 1980-2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Status of rubella and congenital rubella syndrome surveillance, 2005-2009, the World Health Organization European Region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Disseminated measles infection after vaccination in a child with a congenital immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Measles inclusion-body encephalitis caused by the vaccine strain of measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Fever and respiratory distress in an 8-year-old boy receiving therapy for acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Vaccine-associated measles pneumonitis in an adult with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Identifying optimal risk windows for self-controlled case series studies of vaccine safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

SSPE following neonatal measles infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Atypical electroencephalographic pattern in a patient with subacute sclerosing panencephalitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Long-term follow-up of patients with adult-onset subacute sclerosing panencephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

MMR Vaccination and Febrile Seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Thrombocytopenia in infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Recent resurgence of mumps in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

Fluorescent-antibody marker for vaccine-induced rubella antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.057

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.08.057

1 reference

27 August 2017

1 reference